RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsBarking dogs are recognizing that PwC's reiteration on Big Pharma's M&A $5 billion to $15 billion range "sweet-spot" as detailed in PwC's October 2022 success factor report is quickly coming to fruition as the biopharmaceutical industry moves into late 2022 and early 2023 and their patent cliff challenges are yet to be addressed through the acquisition of innovative "bolt-on" companies like ONCY.
October 20, 2022 - "... many companies have recently spent significant time and effort transforming themselves to focus on core therapeutic areas and continued innovation.
With many companies facing patent and pipeline challenges in the 2024-28 period and the fact that biotech valuations appear to be rebalancing, the sweet spot these days for biotech deals appears to be in the $5 billion to $15 billion range."